A prospective, randomized, double‐blind, multicentre, parallel‐group, active controlled study to compare efficacy and safety of biosimilar adalimumab (Exemptia; ZRC‐3197) and adalimumab (Humira) in patients with rheumatoid arthritis

AIM: In this study, efficacy, tolerability and safety of biosimilar adalimumab (Exemptia; Zydus Cadila) was compared with reference adalimumab (Humira; AbbVie) in patients with moderate to severe rheumatoid arthritis (RA). METHOD: In this multicentre, prospective, randomized, double‐blind, active co...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Int J Rheum Dis
Autors principals: Jani, Rajendrakumar H., Gupta, Rajiv, Bhatia, Girish, Rathi, Gaurav, Ashok Kumar, Patnala, Sharma, Reena, Kumar, Uma, Gauri, Liyakat A., Jadhav, Praveen, Bartakke, Girishchandra, Haridas, Vikram, Jain, Dinesh, Mendiratta, Sanjeev K.
Format: Artigo
Idioma:Inglês
Publicat: John Wiley and Sons Inc. 2015
Matèries:
Original Articles
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5215647/
https://ncbi.nlm.nih.gov/pubmed/26176644
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/1756-185X.12711
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars